Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:4
|
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
    Laino, Maria
    Enguita, Monica
    Loricera, Javier
    Moriano Morales, Clara
    Lasa, Carmen
    Calvo Rio, Vanesa
    Narvaez, Javier
    Navarro Guerra, Pablo Ignacio
    Casafont-Sole, Ivette
    Font Urgelles, Judit
    Gallego, Adela
    Carrion-Barbera, Irene
    Quiroga, Patricia
    Castaneda, Santos
    Garcia-Aparicio, Angel
    Belzunegui Otano, Joaquin Maria
    Ramon De Dios, Juan
    Lopez, Marta
    Hernandez, Samuel
    Heredia Martin, Sergi
    Farinas, Aaron
    Navarro, Francisco
    Juan Fragio, Jorge
    Escudero, Carmen
    Ortega Castro, Rafaela
    del Olmo Perez, Leticia
    Pinillos, Valvanera
    Labrador, Eztizen
    Ortega, Mamen
    Castro Perez, Patricia
    Blanco-Madrigal, Juan Maria
    Paulino, Marcos
    Angeles Matias, Maria
    Calvo-Aranda, Enrique
    Peralta, Cilia
    Garcia, Silvia
    Camins-Fabregas, Jordi
    Garijo Bufort, Marta
    Fabregas, Dolores
    Urruticoechea, Ana
    Medina Malone, Miguel
    Cossio Jimenez, Piter Jose
    Perez-Pampin, Eva
    Varas de Dios, Blanca
    Vazquez Galeano, Carlos
    Vegas Revenga, Nuria
    Rusinovich, Olga
    Giner-Serret, Emilio
    Ramon Lamua, Jose
    Aldasoro, Vicente
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4639 - 4643
  • [32] Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids
    Nofer, JR
    Assmann, G
    TRENDS IN CARDIOVASCULAR MEDICINE, 2005, 15 (07) : 265 - 271
  • [33] Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
    Bell, Christopher F.
    Priest, Julie
    Amelio, Justyna
    Song, Xue
    Kan, Hong
    Stott-Miller, Marni
    Limone, Brendan
    Noxon, Virginia
    Costenbader, Karen H.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [34] Can phosphatidylserine enhance atheroprotective activities of high-density lipoprotein?
    Darabi, Maryam
    Kontush, Anatol
    BIOCHIMIE, 2016, 120 : 81 - 86
  • [35] BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT
    Altabas Gonzalez, I.
    Pego-Reigosa, J. M.
    Hernandez-Martin, A.
    Font, J.
    Casafont-Sole, I.
    Roman Ivorra, J. A.
    De la Rubia Navarro, M.
    Galindo, M.
    Salman Monte, T. C.
    Narvaez, J.
    Vidal Montal, P.
    Garcia Villanueva, M. J.
    Fernandez Cid, C. Marras
    Piqueras Garcia, M. M.
    Martinez-Barrio, J.
    Sanchez Lucas, M.
    Cortes-Hernandez, J.
    Penzo, E.
    Calvo-Alen, J.
    De Dios, J. R.
    Tomero Muriel, E.
    Menor-Almagro, R.
    Gandia Martinez, M.
    Gomez-Puerta, J. A.
    Frade-Sosa, B.
    Ramos Giraldez, C.
    Trapero, C.
    Munoz Jimenez, A.
    Moriano, C.
    Diez Alvarez, E.
    Jimenez, N.
    Rua-Figueroa, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1461 - 1462
  • [36] THE COST-EFFECTIVENESS OF BELIMUMAB FOR THE TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN CHINA
    He, X.
    Lloyd, E.
    Asukai, Y.
    Chauhan, D.
    Tang, Z.
    Treur, M.
    VALUE IN HEALTH, 2022, 25 (12) : S123 - S123
  • [37] TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH BELIMUMAB - PROSPECTIVE OBSERVATION OVER 2 YEARS
    Dimitrov, S.
    Hristova, S.
    Bogdanova-Petrova, S.
    Shivacheva, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1480 - 1481
  • [38] BUDGET IMPACT ANALYSIS OF BELIMUMAB IN THE TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN RUSSIAN FEDERATION
    Kulikov, A.
    Komarov, I
    Pochuprina, A.
    VALUE IN HEALTH, 2014, 17 (07) : A525 - A526
  • [39] Effect Of Lipid Composition On The Atheroprotective Properties Of High-Density Lipoprotein-Mimicking Micelles
    Hong, Kristen W.
    Yu, Minzhi
    Mei, Ling
    Olsen, Karl
    Guo, Yanhong
    Luo, Yonghong
    Chen, Eugene
    Schwendeman, Anna
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42
  • [40] Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
    Laino, Maria
    Enguita, Monica
    Navarro, Pablo
    Loricera, Javier
    Garcia-Aparicio, Angel
    Lasa, Carmen
    Calvo Rio, Vanesa
    Gallego, Adela
    Moriano Morales, Clara
    Narvaez, Javier
    Carrion Barbera, Maria Irene
    Camins-Fabregas, Jordi
    Belzunegui Otano, Joaquin Maria
    Urruticoechea, Ana
    del Olmo Perez, Leticia
    Castaneda, Santos
    Quiroga, Patricia
    Casafont-Sole, Ivette
    Jimenez De Aber, Juan Ramon De Dios
    Lopez, Marta
    Font Urgelles, Judit
    Ortega Castro, Rafaela
    Garijo Bufort, Marta
    Juan Fragio, Jorge
    Vazquez, Ignacio
    Ortega, Mamen
    Farinas, Aaron
    Peralta, Cilia
    Maria Blanco, Juan
    Heredia Martin, Sergi
    Valvanera Pinillos, Maria
    Labrador-Sanchez, Eztizen
    Cossio Jimenez, Piter Jose
    Vazquez Galeano, Carlos
    Aldasoro, Vicente
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1174 - 1177